Autoinjectors Market

Autoinjectors Market by Therapy (Rheumatoid Arthritis, Multiple Sclerosis, Anaphylaxis, Cardiovascular Diseases, Diabetes), Type (Disposable, Reusable), Route of administration (Subcutaneous, Intramuscular), End User (Hospital) - Global Forecast to 2025

Report Code: MD 6494 Dec, 2020, by marketsandmarkets.com

[180 Pages Report] The global autoinjectors market is projected to reach USD 104.9 billion by 2025 from USD 46.0 billion in 2020, at a CAGR of 17.9% from 2020 to 2025. Market growth is largely driven by the growing prevalence of targeted therapies, the rising incidence of anaphylaxis, rising preference for self-administration of drugs, usability advantages, the increasing number of regulatory approvals, the availability of generic versions of autoinjectors, favorable reimbursements and government support, and technological advancements. The patent expiry of biologics is also expected to provide growth opportunities for players in the market.

On the other hand, the preference for alternative routes of drug delivery such as oral diabetic agents and nasal epinephrine sprays is expected to limit the adoption of autoinjector devices.

Autoinjectors Market

To know about the assumptions considered for the study, Request for Free Sample Report

COVID-19 Impact on The Autoinjectors Market

The COVID-19 pandemic has resulted in a global healthcare crisis, causing a shift in healthcare delivery in most regions. Most non-essential procedures and in-hospital therapies were deferred in the first half of 2020 to prevent the spread of the infection and ease the toll on healthcare infrastructure. According to researchers at Indiana University, healthcare visits decreased by around 40% in the first six weeks of the pandemic in the US, from early March to mid-April. After restrictions were eased, there has been an overall decline in patients delaying seeking care and treatment in healthcare settings. Moreover, the slowdown in clinical trial recruitment has delayed the introduction of new therapies. These factors could have had a negative impact on the autoinjectors market, especially with their use in healthcare institutions in early 2020.

However, the pandemic’s overall effect on the autoinjectors is considered positive, especially in the forecast period, due to several factors. Firstly, the demand for effective home care and remote monitoring has increased the relevance of autoinjectors for patients to conveniently and easily manage chronic illnesses and allergies without visiting the hospital. This has been especially true in the case of diabetes, Crohn’s disease, and rheumatoid arthritis patients relying on prefilled syringes and autoinjectors to manage their condition at home.

In this regard, Catalent Biologics, a multinational pharmaceutical company, has seen increased demand for autoinjectors since the start of the pandemic. The company also reports that many of its partners have been transitioning their products into autoinjectors to enhance patient convenience and safety. Similarly, SHL Medical, a developer and manufacturer of drug delivery systems, has claimed that the pandemic has been a driver for the autoinjector industry to develop more technologically advanced connected solutions for remote patient monitoring through collaborations with digital healthcare companies. Furthermore, in the biologics space, there has been a shift toward higher delivery volumes and less frequent dosing, which can be achieved through suitably customized autoinjectors, encouraging the development of wearable autoinjectors as well.

In summary, the COVID-19 pandemic has been accelerating the trend of self-injection, empowering patients to have more involvement and control over their treatment. Newer technologies in the autoinjectors market have encouraged this trend, as they allow better management of injection speed, injection site pain, and treatment anxiety.

Autoinjectors Market Dynamics

Driver: Rising incidence of anaphylaxis

Anaphylaxis is a severe, potentially life-threatening allergic reaction to food, drugs, latex, and Hymenoptera stings. According to a NICE study, anaphylaxis-type reactions occur in ~1 in 1,000 of the general population. During general anesthesia, anaphylaxis occurs in 1 in 10,000–20,000 anesthetics. These patients may be denied general anesthesia in the future unless a safe combination of drugs can be identified. Studies on anaphylaxis epidemiology have reported an annual incidence rate of 1.5–50 per 100,000 person-years. However, most reports are from Western countries such as the US, the UK, and Australia. According to a study published in the European Journal of Allergy and Clinical Immunology in 2019, the incidence of anaphylaxis in children worldwide varied widely, ranging from 1 to 761 per 100,000 person-years for total anaphylaxis and 1 to 77 per 100,000 person-years for food-related anaphylaxis.

Epinephrine is the first line of treatment for anaphylaxis. Pharmaceutical companies are coming up with technologically advanced epinephrine autoinjectors (EAIs) for anaphylaxis. Technological advancements include innovative designs, portable devices, autoinjectors with two autoinjectable doses in one device, autoinjectors made with a 0.1-mg dose of epinephrine for infants, autoinjectors made with a 0.5- or 0.75-mg dose of epinephrine for larger adults, autoinjectors with better temperature stability and longer shelf life for epinephrine, impact and weather-resistant casing, and devices that inform patients that the dose was successfully delivered. Factors considered for the improvement of autoinjectors include removal force of safety cap, needle activation force, override force, ejection dosage, needle length, ejection time, dose setting & audible click detection. Such technological advancements are expected to boost the adoption of autoinjectors in the coming years significantly.

Restraint: Alternative drug delivery modes

Traditional injectables with vials and syringes are invasive and painful modes of drug delivery, owing to which patients and care providers are increasingly focusing on alternative routes such as oral, topical, and nasal routes. The oral route is the most preferred as it is easy to use, convenient, cost-effective, safe, and acceptable. Moreover, the introduction of needle-free drug delivery devices such as jet injectors also restricts the market growth. For example, Antares Pharma offers jet injectors to deliver growth hormone in the US, Europe, Asia, and Japan.

Needle-free devices also come with an added advantage-they do not induce needle anxiety, which is a significant deterrent to the greater adoption of injectable drug treatments. Non-compliance among children and adults is mostly attributed to the pain associated with daily injections and the requirements of long-term therapy. According to a study published in the Journal of Advanced Nursing in 2019, most children exhibited needle fear, while prevalence estimates for needle fear ranged from 20–50% in adolescents and 20–30% in young adults. Additionally, about 45% of RA patients reported needle-phobia. As patients suffering from diabetes, rheumatoid arthritis, and growth hormone deficiency, among others, require weekly injection therapy using autoinjectors, needle anxiety is a key restraint to market growth.

Opportunity: Need to limit patient visits and physical contact

The current COVID-19 pandemic has resulted in the implementation of a fresh set of protocols that aim to reduce patient visits to hospitals and clinics in non-emergency conditions to prevent both the transmission of the virus as much as make sure healthcare institutions are not overwhelmed. In this situation, the preference for home-use autoinjectors has risen among patients suffering from chronic illnesses and allergies. This also protects vulnerable high-risk populations from exposure to the virus during hospital visits.

Autoinjectors are being developed to support increased viscosity and concentrations of drugs to reduce administration frequency, thus increasing adherence to recommended drug protocols. These factors present an opportunity for the growth of the autoinjectors market in the current COVID-19 scenario.

Challenge: Development of autoinjectors for multiple drug viscosities

The biggest challenge faced by OEMs is developing single-design autoinjectors for multiple drugs and biologics with varying viscosities. Drugs with different viscosities require springs with different physical characteristics such as composition, length, and thickness to create a spring rate that provides enough power to push higher-viscosity drugs and biologics through the syringe to the needle. Currently, most pharma OEMs lack the knowledge to create autoinjectors capable of delivering multiple drugs and biologics with varying viscosities. However, players are working on overcoming this challenge. For instance, Ypsomed’s Ypsomate 2-step autoinjector has configuration capabilities for different fill volumes and viscosities.  

Autoinjectors Market Interconnections

Rheumatoid Arthritis segment accounted for the largest share of autoinjectors market in 2020.

The autoinjectors market, by therapy, is segmented into rheumatoid arthritis, multiple sclerosis, anaphylaxis, diabetes, multiple sclerosis, and other therapies (includes cardiovascular diseases, migraine treatment, anemia, and progesterone therapy). In 2019, rheumatoid arthritis accounted for the largest share of autoinjectors market. The large share of this segment is mainly attributed to its high prevalence. The increasing incidence of RA fuels the demand for autoinjectors for this therapy segment. According to the CDC, an estimated 43.7 million adults (22.7% of the total population) in the US are affected annually by some form of arthritis, RA, gout, lupus, or fibromyalgia.

Disposable autoinjectors segment accounted for the largest share of autoinjectors market in 2020.

Based on type, the autoinjectors market is segmented into reusable and disposable autoinjectors. In 2019, the disposable autoinjectors segment accounted for the largest share of the global autoinjectors market. Disposable autoinjectors are the most-preferred autoinjectors due to their ease of use and the presence of a built-in glass syringe (eliminates the need of manually loading the glass syringe), which makes it more convenient for patients with reduced dexterity or visual impairments.

Subcutaneous segment is projected to witness fastets growth during the forecast period

Based on route of administration, the autoinjectors market is segmented intramuscular and subcutaneous. Patients use autoinjectors for intramuscular and subcutaneous administration of various drugs for the treatment of diseases such as rheumatoid arthritis, multiple sclerosis, anaphylaxis, diabetes, migraine, anemia, and cancer. The subcutaneous segment accounted for the largest share and it is expected to witness fastest growth during the forecast period. The large share of this segment can primarily be attributed to the growing number of product approvals by regulatory bodies for the treatment of chronic diseases.

Home care settings segment accounted for the largest share of the autoinjectors market in 2019

Based on end users, the autoinjectors market is segmented into home care settings, hospitals & clinics, and ambulatory care settings. The home care settings segment accounted for the largest share of the autoinjectors market in 2019. The large share of this end-user segment can primarily be attributed to the rapid growth in the geriatric population across the globe and the growing need for cost-effective drug administration.

Asia Pacificis projected to witness highest CAGR during the forecast period of 2020–2025.

Geographically, the autoinjectors market is segmented into North America, Europe, the Asia Pacific, Latin America, and Middle East & Africa. Growth in the Asia Pacific market is majorly driven by the large diabetes population and increasing healthcare expenditure which has drawn a number of major autoinjector device manufacturers to this region. These companies are increasing their presence in the Asia Pacific market through several approaches, such as establishing sales offices and partnering with local pharmaceutical companies.

Autoinjectors Market by Region

Key Market Players

Some of the key players operating in the autoinjectors market include AbbVie Inc. (US), Mylan (US), Eli Lilly and Company (US), Ypsomed (Switzerland), Amgen (US), Becton, Dickinson and Company (US), GlaxoSmithKline plc (UK), Johnson & Johnson (US), Teva Pharmaceutical (Israel), Antares Pharma (US), Merck KGaA (Germany).

Scope of the Report:

Report Metric

Details

Market Size Available for Years

2018–2025

Base Year Considered

2019

Forecast Period

2020–2025

Forecast Unit

Value (USD Billion)

Segments Covered

Therapy, Type, Route of Administration and End User

Geographies Covered

  • North America
  • Europe
  • Asia Pacific
  • Latin America
  • Middle East & Africa

The research report categorizes the autoinjectors market into the following segments and sub-segments:

By Therapy

  • Rheumatoid Arthritis
  • Multiple Sclerosis
  • Diabetes
  • Anaphylaxis
  • Other Therapies

By Type

  • Disposable Autoinjectors
  • Reusable Autoinjectors

By Route of Administration

  • Subcutaneous
  • Intramuscular

By End User

  • Home Care Settings
  • Hospitals & Clinics
  • Ambulatory Care Settings

By Region

  • North America
    • US
    • Canada
  • Europe
    • Germany
    • UK
    • France
    • Italy
    • Spain
    • Rest of Europe
  • Asia-Pacific
    • China
    • Japan
    • India
    • Rest of Asia-Pacific
  • Latin America
  • Middle East and Africa

Recent Developments

  • In August 2020, Antares Pharma (US) signed an agreement with Lunatus Global Medical Supplies (Dubai). In this agreement, Antares will supply packaged products to Lunatus and Lunatus will submit and obtain regulatory approval for XYOSTED in the UAE and Saudi Arabia as well as promote, market, and distribute XYOSTED in these two countries.
  • In March 2020, SHL Medical (Switzerland) acquired Weibel CDS (Switzerland). This acquisition aimed at strengthening SHL Medical’s ability to provide more advanced drug delivery systems based on human-centered designs and functionality.
  • In January 2020, Eli Lilly invested USD 470 million and created over 460 new jobs in Durham, NC. This expansion brought a new state-of-the-art pharmaceutical manufacturing facility to North Carolina’s research triangle park.
  • In November 2019, Becton, Dickinson and Company (US) launched a disposable autoinjector namely BD Intevia 1ml Disposable Autoinjector. This activity will strengthen company’s autoinjector’s portfolio.

Frequently Asked Questions (FAQ):

To speak to our analyst for a discussion on the above findings, click Speak to Analyst

TABLE OF CONTENTS

1 INTRODUCTION (Page No. - 23)
    1.1 OBJECTIVES OF THE STUDY
    1.2 MARKET DEFINITION & SCOPE
    1.3 MARKETS COVERED
           FIGURE 1 AUTOINJECTORS MARKET SEGMENTATION
    1.4 YEARS CONSIDERED FOR THE STUDY
    1.5 CURRENCY
    1.6 LIMITATIONS
    1.7 STAKEHOLDERS
    1.8 SUMMARY OF CHANGES

2 RESEARCH METHODOLOGY (Page No. - 27)
    2.1 RESEARCH APPROACH
           FIGURE 2 RESEARCH DESIGN
           2.1.1 SECONDARY DATA
                    2.1.1.1 Key data from secondary sources
           2.1.2 PRIMARY DATA
                    2.1.2.1 Key data from primary sources
                    2.1.2.2 Breakdown of primaries
           FIGURE 4 BREAKDOWN OF PRIMARY INTERVIEWS (SUPPLY SIDE): BY COMPANY TYPE, DESIGNATION, AND REGION
           FIGURE 5 BREAKDOWN OF PRIMARY INTERVIEWS (DEMAND SIDE): BY END USER, DESIGNATION, AND REGION
    2.2 MARKET SIZE ESTIMATION
           FIGURE 6 MARKET SIZE ESTIMATION: REVENUE SHARE ANALYSIS (2019)
           FIGURE 7 MARKET SIZE ESTIMATION: REVENUE SHARE ANALYSIS (2019)
           FIGURE 8 SUPPLY-SIDE ANALYSIS: AUTOINJECTORS MARKET (2019)
           FIGURE 9 CAGR PROJECTIONS: SUPPLY-SIDE ANALYSIS OF THE AUTOINJECTORS MARKET (2019)
           FIGURE 10 CAGR PROJECTIONS FROM THE ANALYSIS OF DRIVERS, RESTRAINTS, OPPORTUNITIES, AND CHALLENGES OF THE AUTOINJECTORS MARKET  (2020–2025)
    2.3 MARKET BREAKDOWN & DATA TRIANGULATION
    2.4 MARKET SHARE ESTIMATION
    2.5 ASSUMPTIONS FOR THE STUDY
    2.6 COVID-19 HEALTH ASSESSMENT
    2.7 COVID-19 ECONOMIC ASSESSMENT
    2.8 ASSESSMENT OF THE IMPACT OF COVID-19 ON THE ECONOMIC SCENARIO
           FIGURE 12 CRITERIA IMPACTING THE GLOBAL ECONOMY
           FIGURE 13 RECOVERY SCENARIO OF THE GLOBAL ECONOMY

3 EXECUTIVE SUMMARY (Page No. - 42)
           FIGURE 14 AUTOINJECTORS MARKET, BY THERAPY, 2020 VS. 2025 (USD MILLION)
           FIGURE 15 AUTOINJECTORS MARKET, BY TYPE, 2020 VS. 2025 (USD MILLION)
           FIGURE 16 AUTOINJECTORS MARKET, BY ROUTE OF ADMINISTRATION,  2020 VS. 2025 (USD MILLION)
           FIGURE 17 AUTOINJECTORS MARKET, BY END USER, 2020 VS. 2025 (USD MILLION)
           FIGURE 18 GEOGRAPHICAL SNAPSHOT OF THE AUTOINJECTORS MARKET

4 PREMIUM INSIGHTS (Page No. - 46)
    4.1 AUTOINJECTORS MARKET OVERVIEW
           FIGURE 19 GROWING PREVALENCE OF TARGETED THERAPIES AND RISING PREFERENCE FOR SELF-ADMINISTRATION OF DRUGS TO DRIVE MARKET GROWTH
    4.2 ASIA PACIFIC: AUTOINJECTORS MARKET, BY THERAPY AND COUNTRY (2020)
           FIGURE 20 RHEUMATOID ARTHRITIS SEGMENT TO ACCOUNT FOR THE LARGEST SHARE OF THE APAC MARKET IN 2020
    4.3 AUTOINJECTORS MARKET, BY REGION, 2020−2025
           FIGURE 21 NORTH AMERICA WILL CONTINUE TO DOMINATE THE AUTOINJECTORS MARKET IN THE FORECAST PERIOD
    4.4 AUTOINJECTORS MARKET: DEVELOPED VS. DEVELOPING MARKETS
           FIGURE 22 DEVELOPING MARKETS TO REGISTER HIGHER GROWTH DURING THE FORECAST PERIOD

5 MARKET OVERVIEW (Page No. - 49)
    5.1 INTRODUCTION
    5.2 MARKET DYNAMICS
           FIGURE 23 AUTOINJECTORS MARKET: DRIVERS, RESTRAINTS, OPPORTUNITIES,  & CHALLENGES
           5.2.1 DRIVERS
                    5.2.1.1 Growing prevalence of targeted therapies
           FIGURE 24 CHINA: TOTAL DIABETIC POPULATION FROM 2010 TO 2045
                    5.2.1.2 Rising incidence of anaphylaxis
                    5.2.1.3 Increasing number of regulatory approvals
           TABLE 1 RECENT APPROVALS OF AUTOINJECTOR DEVICES ACROSS THE GLOBE
                    5.2.1.4 Availability of generic versions of autoinjectors
                    5.2.1.5 Favorable reimbursements and government support
                    5.2.1.6 Ease of use increasing the preference for self-administration
           5.2.2 RESTRAINTS
                    5.2.2.1 Alternative drug delivery modes
                    5.2.2.2 Research, development, and launch of oral diabetic agents and oral insulin
                    5.2.2.3 Development of nasal epinephrine sprays
           5.2.3 OPPORTUNITIES
                    5.2.3.1 Patent expiry of biologics to drive the demand for biosimilars
           TABLE 2 PATENT EXPIRY OF KEY BIOLOGICS
                    5.2.3.2 Need to limit patient visits and physical contact
           5.2.4 CHALLENGES
                    5.2.4.1 Development of autoinjectors for multiple drug viscosities
                    5.2.4.2 Lack of proper training for using autoinjectors
    5.3 COVID-19 IMPACT ON THE AUTOINJECTORS MARKET
    5.4 AVERAGE SELLING PRICE TRENDS
           TABLE 3 AVERAGE SELLING PRICE OF EPINEPHRINE AUTOINJECTORS, BY REGION, 2015 VS. 2020
    5.5 VALUE CHAIN ANALYSIS
           FIGURE 25 AUTOINJECTORS MARKET: VALUE CHAIN ANALYSIS (2019)
    5.6 ECOSYSTEM ANALYSIS
           FIGURE 26 ECOSYSTEM: AUTOINJECTORS MARKET (2019)

6 INDUSTRY INSIGHTS (Page No. - 59)
    6.1 INTRODUCTION
    6.2 INDUSTRY TRENDS
           6.2.1 ADVANCEMENTS IN AUTOINJECTOR DESIGN
           6.2.2 WEARABLE AUTOINJECTORS
           6.2.3 CONNECTED AUTOINJECTOR DEVICES

7 AUTOINJECTORS MARKET, BY THERAPY (Page No. - 61)
    7.1 INTRODUCTION
           TABLE 4 AUTOINJECTORS MARKET, BY THERAPY, 2018–2025 (USD MILLION)
    7.2 RHEUMATOID ARTHRITIS
           7.2.1 INCREASING INCIDENCE OF RA HAS BOOSTED THE ADOPTION OF AUTOINJECTORS
           TABLE 5 AUTOINJECTORS MARKET FOR RHEUMATOID ARTHRITIS, BY COUNTRY,  2018–2025 (USD MILLION)
    7.3 DIABETES
           7.3.1 LARGE PATIENT POPULATION TO STIMULATE THE DEMAND FOR AUTOINJECTORS DURING THE FORECAST PERIOD
           FIGURE 27 DIABETIC POPULATION: TOP COUNTRIES/TERRITORIES (20–79 YEARS),  2019 VS. 2030 VS. 2045
           TABLE 6 AUTOINJECTORS MARKET FOR DIABETES, BY COUNTRY,2018–2025 (USD MILLION)
    7.4 MULTIPLE SCLEROSIS
           7.4.1 INFLUX OF GENERICS IS EXPECTED TO NEGATIVELY IMPACT MARKET GROWTH DURING THE FORECAST PERIOD
           FIGURE 28 NUMBER OF PEOPLE WITH MS (PER 100,000) - WHO REGIONS
           TABLE 7 AUTOINJECTORS MARKET FOR MULTIPLE SCLEROSIS, BY COUNTRY, 2018–2025 (USD MILLION)
    7.5 ANAPHYLAXIS
           7.5.1 INCREASING PREVALENCE OF FOOD ALLERGIES TO DRIVE THE UPTAKE OF AUTOINJECTORS
           TABLE 8 AUTOINJECTORS MARKET FOR ANAPHYLAXIS, BY COUNTRY,2018–2025 (USD MILLION)
    7.6 OTHER THERAPIES
           TABLE 9 AUTOINJECTORS MARKET FOR OTHER THERAPIES, BY COUNTRY,  2018–2025 (USD MILLION)
    7.7 IMPACT OF COVID-19 ON THE THERAPEUTIC APPLICATIONS OF AUTOINJECTORS

8 AUTOINJECTORS MARKET, BY TYPE (Page No. - 69)
    8.1 INTRODUCTION
           TABLE 10 COMPARISON OF DISPOSABLE & REUSABLE AUTOINJECTORS
           TABLE 11 AUTOINJECTORS MARKET, BY TYPE, 2018–2025 (USD MILLION)
    8.2 DISPOSABLE AUTOINJECTORS
           8.2.1 DISPOSABLE AUTOINJECTORS ARE CONVENIENT FOR PATIENTS WITH REDUCED DEXTERITY OR VISUAL IMPAIRMENTS
           TABLE 12 DISPOSABLE AUTOINJECTORS MARKET, BY COUNTRY, 2018–2025 (USD MILLION)
    8.3 REUSABLE AUTOINJECTORS
           8.3.1 REUSABLE AUTOINJECTORS ARE MORE ECONOMICAL AS COMPARED TO DISPOSABLE AUTOINJECTORS
           TABLE 13 REUSABLE AUTOINJECTORS MARKET, BY COUNTRY,2018–2025 (USD MILLION)

9 AUTOINJECTORS MARKET, BY ROUTE OF ADMINISTRATION (Page No. - 73)
    9.1 INTRODUCTION
           TABLE 14 AUTOINJECTORS MARKET, BY ROUTE OF ADMINISTRATION,2018–2025 (USD MILLION)
    9.2 SUBCUTANEOUS
           9.2.1 GROWING NUMBER OF PRODUCT APPROVALS BY REGULATORY BODIES WILL SUPPORT THE GROWTH OF THIS MARKET SEGMENT
           TABLE 15 SUBCUTANEOUS AUTOINJECTORS, BY COUNTRY, 2018–2025 (USD MILLION)
    9.3 INTRAMUSCULAR
           9.3.1 INTRAMUSCULAR ROUTE OF ADMINISTRATION ENABLES MEDICATION TO BE ABSORBED QUICKLY—A KEY FACTOR DRIVING MARKET GROWTH
           TABLE 16 EXAMPLES OF INTRAMUSCULAR AUTOINJECTORS
           TABLE 17 INTRAMUSCULAR AUTOINJECTORS MARKET, BY COUNTRY, 2018–2025 (USD MILLION)

10 AUTOINJECTORS MARKET, BY END USER (Page No. - 78)
     10.1 INTRODUCTION
           TABLE 18 AUTOINJECTORS MARKET, BY END USER, 2018–2025 (USD MILLION)
     10.2 HOME CARE SETTINGS
             10.2.1 HOME CARE THERAPIES ARE COST-EFFECTIVE COMPARED TO TREATMENTS IN HOSPITALS—A KEY FACTOR DRIVING MARKET GROWTH
           TABLE 19 AUTOINJECTORS MARKET FOR HOME CARE SETTINGS, BY COUNTRY,  2018–2025 (USD MILLION)
     10.3 HOSPITALS & CLINICS
             10.3.1 HIGH USAGE OF AUTOINJECTORS IN EMERGENCY CASES IN HOSPITALS & CLINICS WILL DRIVE MARKET GROWTH
           TABLE 20 AUTOINJECTORS MARKET FOR HOSPITALS & CLINICS, BY COUNTRY, 2018–2025 (USD MILLION)
     10.4 AMBULATORY CARE SETTINGS
             10.4.1 INCREASING NUMBER OF PATIENTS IN AMBULATORY CARE SETTINGS TO DRIVE THE DEMAND FOR AUTOINJECTORS
           TABLE 21 AUTOINJECTORS MARKET FOR AMBULATORY CARE SETTINGS, BY COUNTRY,  2018–2025 (USD MILLION)

11 AUTOINJECTORS MARKET, BY REGION (Page No. - 83)
     11.1 REGIONAL COVID-19 IMPACT: SUMMARY
     11.2 INTRODUCTION
           FIGURE 29 AUTOINJECTORS MARKET: GEOGRAPHIC GROWTH OPPORTUNITIES
           TABLE 22 AUTOINJECTORS MARKET, BY REGION, 2018–2025 (USD MILLION)
     11.3 NORTH AMERICA
           FIGURE 30 NORTH AMERICA: AUTOINJECTORS MARKET SNAPSHOT
           TABLE 23 NORTH AMERICA: AUTOINJECTORS MARKET, BY COUNTRY, 2018–2025 (USD MILLION)
           TABLE 24 NORTH AMERICA: AUTOINJECTORS MARKET, BY THERAPY,2018–2025 (USD MILLION)
           TABLE 25 NORTH AMERICA: AUTOINJECTORS MARKET, BY TYPE,2018–2025 (USD MILLION)
           TABLE 26 NORTH AMERICA: AUTOINJECTORS MARKET, BY ROUTE OF ADMINISTRATION,  2018–2025 (USD MILLION)
           TABLE 27 NORTH AMERICA: AUTOINJECTORS MARKET, BY END USER, 2018–2025 (USD MILLION)
             11.3.1 US
                        11.3.1.1 The US is the largest market for autoinjectors in North America
           TABLE 28 AUTOINJECTORS APPROVED BY THE FDA, 2017-2019
           TABLE 29 US: AUTOINJECTORS MARKET, BY THERAPY, 2018–2025 (USD MILLION)
           TABLE 30 US: AUTOINJECTORS MARKET, BY TYPE, 2018–2025 (USD MILLION)
           TABLE 31 US: AUTOINJECTORS MARKET, BY ROUTE OF ADMINISTRATION, 2018–2025 (USD MILLION)
           TABLE 32 US: AUTOINJECTORS MARKET, BY END USER, 2018–2025 (USD MILLION)
             11.3.2 CANADA
                        11.3.2.1 Rising prevalence of chronic diseases to drive the market growth
           TABLE 33 CANADA: AUTOINJECTORS MARKET, BY THERAPY, 2018–2025 (USD MILLION)
           TABLE 34 CANADA: AUTOINJECTORS MARKET, BY TYPE, 2018–2025 (USD MILLION)
           TABLE 35 CANADA: AUTOINJECTORS MARKET, BY ROUTE OF ADMINISTRATION,  2018–2025 (USD MILLION)
           TABLE 36 CANADA: AUTOINJECTORS MARKET, BY END USER, 2018–2025 (USD MILLION)
     11.4 EUROPE
           FIGURE 31 EUROPE: AUTOINJECTORS MARKET SNAPSHOT
           TABLE 37 EUROPE: AUTOINJECTORS MARKET, BY COUNTRY,2018–2025 (USD MILLION)
           TABLE 38 EUROPE: AUTOINJECTORS MARKET, BY THERAPY, 2018–2025 (USD MILLION)
           TABLE 39 EUROPE: AUTOINJECTORS MARKET, BY TYPE, 2018–2025 (USD MILLION)
           TABLE 40 EUROPE: AUTOINJECTORS MARKET, BY ROUTE OF ADMINISTRATION,  2018–2025 (USD MILLION)
           TABLE 41 EUROPE: AUTOINJECTORS MARKET, BY END USER, 2018–2025 (USD MILLION)
             11.4.1 GERMANY
                        11.4.1.1 Germany is the largest market for autoinjectors in Europe
           TABLE 42 GERMANY: AUTOINJECTORS MARKET, BY THERAPY, 2018–2025 (USD MILLION)
           TABLE 43 GERMANY: AUTOINJECTORS MARKET, BY TYPE, 2018–2025 (USD MILLION)
           TABLE 44 GERMANY: AUTOINJECTORS MARKET, BY ROUTE OF ADMINISTRATION,  2018–2025 (USD MILLION)
           TABLE 45 GERMANY: AUTOINJECTORS MARKET, BY END USER, 2018–2025 (USD MILLION)
             11.4.2 UK
                        11.4.2.1 The UK has the highest rate of allergic conditions globally—a key factor expected to boost the market growth
           TABLE 46 UK: AUTOINJECTORS MARKET, BY THERAPY, 2018–2025 (USD MILLION)
           TABLE 47 UK: AUTOINJECTORS MARKET, BY TYPE, 2018–2025 (USD MILLION)
           TABLE 48 UK: AUTOINJECTORS MARKET, BY ROUTE OF ADMINISTRATION, 2018–2025 (USD MILLION)
           TABLE 49 UK: AUTOINJECTORS MARKET, BY END USER, 2018–2025 (USD MILLION)
             11.4.3 FRANCE
                        11.4.3.1 Rising geriatric population to support market growth
           TABLE 50 FRANCE: AUTOINJECTORS MARKET, BY THERAPY, 2018–2025 (USD MILLION)
           TABLE 51 FRANCE: AUTOINJECTORS MARKET, BY TYPE, 2018–2025 (USD MILLION)
           TABLE 52 FRANCE: AUTOINJECTORS MARKET, BY ROUTE OF ADMINISTRATION,  2018–2025 (USD MILLION)
           TABLE 53 FRANCE: AUTOINJECTORS MARKET, BY END USER,2018–2025 (USD MILLION)
             11.4.4 ITALY
                        11.4.4.1 Improving economic conditions and rising per capita income to propel market growth
           TABLE 54 ITALY: AUTOINJECTORS MARKET, BY THERAPY, 2018–2025 (USD MILLION)
           TABLE 55 ITALY: AUTOINJECTORS MARKET, BY TYPE, 2018–2025 (USD MILLION)
           TABLE 56 ITALY: AUTOINJECTORS MARKET, BY ROUTE OF ADMINISTRATION,  2018–2025 (USD MILLION)
           TABLE 57 ITALY: AUTOINJECTORS MARKET, BY END USER, 2018–2025 (USD MILLION)
             11.4.5 SPAIN
                        11.4.5.1 Favorable reimbursement scenario coupled with the rising prevalence of chronic diseases to support market growth
           TABLE 58 SPAIN: AUTOINJECTORS MARKET, BY THERAPY, 2018–2025 (USD MILLION)
           TABLE 59 SPAIN: AUTOINJECTORS MARKET, BY TYPE, 2018–2025 (USD MILLION)
           TABLE 60 SPAIN: AUTOINJECTORS MARKET, BY ROUTE OF ADMINISTRATION,  2018–2025 (USD MILLION)
           TABLE 61 SPAIN: AUTOINJECTORS MARKET, BY END USER, 2018–2025 (USD MILLION)
             11.4.6 REST OF EUROPE
           TABLE 62 ROE: AUTOINJECTORS MARKET, BY THERAPY, 2018–2025 (USD MILLION)
           TABLE 63 ROE: AUTOINJECTORS MARKET, BY TYPE, 2018–2025 (USD MILLION)
           TABLE 64 ROE: AUTOINJECTORS MARKET, BY ROUTE OF ADMINISTRATION,2018–2025 (USD MILLION)
           TABLE 65 ROE: AUTOINJECTORS MARKET, BY END USER, 2018–2025 (USD MILLION)
     11.5 ASIA PACIFIC
           FIGURE 32 ASIA PACIFIC: AUTOINJECTORS MARKET SNAPSHOT
           TABLE 66 ASIA PACIFIC: AUTOINJECTORS MARKET, BY COUNTRY, 2018–2025 (USD MILLION)
           TABLE 67 ASIA PACIFIC: AUTOINJECTORS MARKET, BY THERAPY,2018–2025 (USD MILLION)
           TABLE 68 ASIA PACIFIC: AUTOINJECTORS MARKET, BY TYPE,2018–2025 (USD MILLION)
           TABLE 69 ASIA PACIFIC: AUTOINJECTORS MARKET, BY ROUTE OF ADMINISTRATION,  2018–2025 (USD MILLION)
           TABLE 70 ASIA PACIFIC: AUTOINJECTORS MARKET, BY END USER,2018–2025 (USD MILLION)
             11.5.1 JAPAN
                        11.5.1.1 High adoption of autoinjectors and approval of several injectable devices to boost the market growth
           TABLE 71 JAPAN: AUTOINJECTORS MARKET, BY THERAPY, 2018–2025 (USD MILLION)
           TABLE 72 JAPAN: AUTOINJECTORS MARKET, BY TYPE, 2018–2025 (USD MILLION)
           TABLE 73 JAPAN: AUTOINJECTORS MARKET, BY ROUTE OF ADMINISTRATION, 2018–2025 (USD MILLION)
           TABLE 74 JAPAN: AUTOINJECTORS MARKET, BY END USER, 2018–2025 (USD MILLION)
             11.5.2 CHINA
                        11.5.2.1 Food allergies and anaphylaxis have become a major public health burden in China
           TABLE 75 CHINA: AUTOINJECTORS MARKET, BY THERAPY, 2018–2025 (USD MILLION)
           TABLE 76 CHINA: AUTOINJECTORS MARKET, BY TYPE, 2018–2025 (USD MILLION)
           TABLE 77 CHINA: AUTOINJECTORS MARKET, BY ROUTE OF ADMINISTRATION, 2018–2025 (USD MILLION)
           TABLE 78 CHINA: AUTOINJECTORS MARKET, BY END USER, 2018–2025 (USD MILLION)
             11.5.3 INDIA
                        11.5.3.1 Increasing burden of chronic diseases such as diabetes and CVD is expected to drive the demand for autoinjectors in India
           TABLE 79 INDIA: AUTOINJECTORS MARKET, BY THERAPY, 2018–2025 (USD MILLION)
           TABLE 80 INDIA: AUTOINJECTORS MARKET, BY TYPE, 2018–2025 (USD MILLION)
           TABLE 81 INDIA: AUTOINJECTORS MARKET, BY ROUTE OF ADMINISTRATION,  2018–2025 (USD MILLION)
           TABLE 82 INDIA: AUTOINJECTORS MARKET, BY END USER, 2018–2025 (USD MILLION)
             11.5.4 ROAPAC
           TABLE 83 ROAPAC: AUTOINJECTORS MARKET, BY THERAPY, 2018–2025 (USD MILLION)
           TABLE 84 ROAPAC: AUTOINJECTORS MARKET, BY TYPE, 2018–2025 (USD MILLION)
           TABLE 85 ROAPAC: AUTOINJECTORS MARKET, BY ROUTE OF ADMINISTRATION,2018–2025 (USD MILLION)
           TABLE 86 ROAPAC: AUTOINJECTORS MARKET, BY END USER, 2018–2025 (USD MILLION)
     11.6 LATIN AMERICA
             11.6.1 RISING ELDERLY POPULATION IN COUNTRIES SUCH AS BRAZIL AND MEXICO TO SUPPORT MARKET GROWTH
           TABLE 87 LATIN AMERICA: AUTOINJECTORS MARKET, BY THERAPY, 2018–2025 (USD MILLION)
           TABLE 88 LATIN AMERICA: AUTOINJECTORS MARKET, BY TYPE, 2018–2025 (USD MILLION)
           TABLE 89 LATIN AMERICA: AUTOINJECTORS MARKET, BY ROUTE OF ADMINISTRATION,  2018–2025 (USD MILLION)
           TABLE 90 LATIN AMERICA: AUTOINJECTORS MARKET, BY END USER, 2018–2025 (USD MILLION)
     11.7 MIDDLE EAST & AFRICA
             11.7.1 IMPLEMENTATION OF FAVORABLE REFORMS IN AFRICA AS WELL AS MIDDLE EASTERN COUNTRIES TO DRIVE MARKET GROWTH
           TABLE 91 MEA: AUTOINJECTORS MARKET, BY THERAPY, 2018–2025 (USD MILLION)
           TABLE 92 MEA: AUTOINJECTORS MARKET, BY TYPE, 2018–2025 (USD MILLION)
           TABLE 93 MEA: AUTOINJECTORS MARKET, BY ROUTE OF ADMINISTRATION, 2018–2025 (USD MILLION)
           TABLE 94 MEA: AUTOINJECTORS MARKET, BY END USER, 2018–2025 (USD MILLION)

12 COMPANY EVALUATION MATRIX (Page No. - 124)
     12.1 MARKET SHARE ANALYSIS
           FIGURE 33 AUTOINJECTORS MARKET SHARE ANALYSIS, BY KEY PLAYER, 2019
     12.2 VENDOR DIVE
             12.2.1 STARS
             12.2.2 EMERGING LEADERS
             12.2.3 PERVASIVE PLAYERS
             12.2.4 EMERGING COMPANIES
           FIGURE 34 AUTOINJECTORS MARKET: COMPETITIVE LEADERSHIP MAPPING, 2019
     12.3 COMPETITIVE LEADERSHIP MAPPING FOR SMALL & MEDIUM-SIZED ENTERPRISES (SMES)/STARTUPS
             12.3.1 PROGRESSIVE COMPANIES
             12.3.2 STARTING BLOCKS
             12.3.3 RESPONSIVE COMPANIES
             12.3.4 DYNAMIC COMPANIES
           FIGURE 35 AUTOINJECTORS MARKET: COMPETITIVE LEADERSHIP MAPPING FOR START-UPS, 2019

13 COMPETITIVE LANDSCAPE (Page No. - 128)
     13.1 INTRODUCTION
           FIGURE 36 KEY DEVELOPMENTS IN THE AUTOINJECTORS MARKET
           FIGURE 37 GROWTH STRATEGY MATRIX
     13.2 PRODUCT PORTFOLIO MATRIX
             13.2.1 THERAPY
     13.3 AUTOINJECTORS MARKET: GEOGRAPHICAL ASSESSMENT
           FIGURE 38 GEOGRAPHIC ASSESSMENT OF KEY PLAYERS IN THE AUTOINJECTORS MARKET (2019)
     13.4 AUTOINJECTORS MARKET: R&D EXPENDITURE
           FIGURE 39 R&D EXPENDITURE OF KEY PLAYERS IN THE AUTOINJECTORS MARKET (2019)
     13.5 COMPETITIVE SITUATIONS AND TRENDS
             13.5.1 PRODUCT LAUNCHES & APPROVALS
           TABLE 95 PRODUCT LAUNCHES & APPROVALS (2018–2020)
             13.5.2 PARTNERSHIPS, COLLABORATIONS, AND AGREEMENTS
           TABLE 96 PARTNERSHIPS, COLLABORATIONS, AND AGREEMENTS (2018–2020)
             13.5.3 ACQUISITIONS
           TABLE 97 ACQUISITIONS (2020)
             13.5.4 EXPANSIONS
           TABLE 98 EXPANSIONS (2018–2020)
             13.5.5 OTHER DEVELOPMENTS
           TABLE 99 OTHER DEVELOPMENTS (2019–2020)

14 COMPANY PROFILES (Page No. - 135)
(Business Overview, Products Offered, Recent Developments, MNM View, and Strategic Overview)* 
     14.1 ABBVIE INC.
           FIGURE 40 ABBVIE INC.: COMPANY SNAPSHOT (2019)
     14.2 AMGEN
           FIGURE 41 AMGEN: COMPANY SNAPSHOT (2019)
     14.3 ELI LILLY AND COMPANY
           FIGURE 42 ELI LILLY AND COMPANY: COMPANY SNAPSHOT (2019)
     14.4 MYLAN
           FIGURE 43 MYLAN: COMPANY SNAPSHOT (2019)
     14.5 YPSOMED
           FIGURE 44 YPSOMED: COMPANY SNAPSHOT (2019)
     14.6 BECTON, DICKINSON AND COMPANY
           FIGURE 45 BD: COMPANY SNAPSHOT (2019)
     14.7 GLAXOSMITHKLINE PLC
           FIGURE 46 GLAXOSMITHKLINE PLC: COMPANY SNAPSHOT (2019)
     14.8 JOHNSON & JOHNSON (J&J)
           FIGURE 47 JOHNSON & JOHNSON: COMPANY SNAPSHOT (2019)
     14.9 TEVA PHARMACEUTICAL INDUSTRIES
           FIGURE 48 TEVA PHARMACEUTICAL INDUSTRIES: COMPANY SNAPSHOT (2019)
     14.10 ANTARES PHARMA, INC.
           FIGURE 49 ANTARES PHARMA: COMPANY SNAPSHOT (2019)
     14.11 MERCK KGAA
           FIGURE 50 MERCK KGAA: COMPANY SNAPSHOT (2019)
     14.12 MERIDIAN MEDICAL TECHNOLOGIES, INC. (A PFIZER COMPANY)
           FIGURE 51 PFIZER: COMPANY SNAPSHOT (2019)
     14.13 F. HOFFMANN-LA ROCHE
           FIGURE 52 F. HOFFMANN-LA ROCHE LTD.: COMPANY SNAPSHOT (2019)
     14.14 BESPAK
           FIGURE 53 CONSORT MEDICAL PLC: COMPANY SNAPSHOT (2019)
     14.15 BAYER AG
           FIGURE 54 BAYER AG: COMPANY SNAPSHOT (2019)
     14.16 BRISTOL-MYERS SQUIBB COMPANY
           FIGURE 55 BRISTOL-MYERS SQUIBB COMPANY: COMPANY SNAPSHOT (2019)
     14.17 SHL MEDICAL
     14.18 HASELMEIER
     14.19 OWEN MUMFORD
     14.20 RAVIMED
     14.21 MEDECA PHARMA AB
*Details on Business Overview, Products Offered, Recent Developments, MNM View, and Strategic Overview might not be captured in case of unlisted companies. 

15 APPENDIX (Page No. - 173)
     15.1 INSIGHTS FROM INDUSTRY EXPERTS
     15.2 DISCUSSION GUIDE
     15.3 KNOWLEDGE STORE: MARKETSANDMARKETS’  SUBSCRIPTION PORTAL
     15.4 AVAILABLE CUSTOMIZATIONS
     15.5 RELATED REPORTS
     15.6 AUTHOR DETAILS

This study involved four major activities in estimating the current autoinjectors market size. Exhaustive research was conducted to collect information on the market as well as its peer and parent markets. The next step was to validate these findings, assumptions, and sizing with industry experts across the value chain through primary research. Both top-down and bottom-up approaches were employed to estimate the number of breast lesion localization procedures and the value market. After that, market breakdown and data triangulation procedures were used to estimate the market size of segments and subsegments.

Secondary Research

This research study involved the usage of widespread secondary sources; directories; databases such as Bloomberg Business, Factiva, and Dun & Bradstreet; white papers; annual reports; company house documents; investor presentations; and SEC filings of companies. Secondary research was used to identify and collect information useful for the extensive, technical, market-oriented, and commercial study of the market. It was also used to obtain important information about the key players, market classification and segmentation according to industry trends to the bottom-most level, and key developments related to market and technology perspectives.

Primary Research

The autoinjectors market comprises several stakeholders, such as raw material suppliers, manufacturers of autoinjectors devices, and regulatory organizations in the supply chain. Various primary sources from both the supply and demand sides of the market were interviewed to obtain qualitative and quantitative information. The primary interviewees from the demand side include professionals such as company vice presidents, company’s C-level executives, managers, product managers, department heads, professors, and research scientists. The primary sources from the supply side include key CEOs, VPs and managing directors, marketing heads/directors and sales directors, marketing managers, regional/area sales managers, export/import, heads/managers, and product managers/technology experts.

Market Size Estimation

Both the top-down and bottom-up approaches were used to estimate and validate the total size of the autoinjectors market (value and volume). These approaches were also used extensively to estimate the size of various subsegments in the market. After arriving at the overall market size—using the market size estimation processes explained above—the market was split into several segments and subsegments. To complete the overall market engineering process and arrive at the exact statistics of each market segment and subsegment, data triangulation, and market breakdown procedures were employed, wherever applicable. The data was triangulated by studying various factors and trends from both the demand and supply sides of the autoinjectors industry.

Autoinjectors Market  Size, and Share

To know about the assumptions considered for the study, download the pdf brochure

Data Triangulation

After arriving at the overall market size-using the market size estimation processes as explained above-the market was split into several segments and subsegments. In order to complete the overall market engineering process and arrive at the exact statistics of each market segment and subsegment, the data triangulation and market breakdown procedures were employed, wherever applicable. The data was triangulated by studying various factors and trends from both, the demand and supply sides.

Approach to calculate the revenue of different players in the autoinjectors market

The size of the global autoinjectors market was obtained from annual reports, SEC filings, online publications, and extensive primary interviews. A percentage split was applied to arrive at the size of market segments. Further splits were applied to arrive at the size for each sub-segment. Primary participants validated these percentage splits. The country-level market sizes obtained from the annual reports, SEC filings, online publications, and extensive primary interviews were added up to reach the total market size for regions. By adding up the market sizes for all the regions, the global autoinjectors market was derived.

Approach to derive the market size and estimate market growth

The market size and market growth were estimated through primary interviews on a regional and global level. All responses were collated, and a weighted average was taken to derive a probabilistic estimate of the market size and growth rate.

Objectives of the Study

  • To define, describe, analyze, and forecast the autoinjectors market by therapy, type, route of administration, end user and region
  • To provide detailed information about the major factors influencing the market growth (such as drivers, restraints, opportunities, and challenges)
  • To strategically analyze micromarkets with respect to individual growth trends, prospects, and contributions to the overall autoinjectors market
  • To analyze market opportunities for stakeholders and provide details of the competitive landscape for key players
  • To forecast the size of market segments in North America, Europe, the Asia Pacific, Latin America, and the Middle East & Africa
  • To profile key players and comprehensively analyze their market shares and core competencies in the autoinjectors market
  • To track and analyze competitive developments such as partnerships, agreements, acquisitions, product launches, and expansions in the autoinjectors market

Available Customizations

With the given market data, MarketsandMarkets offers customizations as per the company’s specific needs. The following customization options are available for the report:

Product Analysis

  • Product matrix, which gives a detailed comparison of the product portfolios of the top companies

Geographic Analysis

  • Further breakdown of the RoAPAC market into South Korea, New Zealand, and other countries Further breakdown of the RoE market into Belgium, Russia, the Netherlands, Switzerland, and other countries
COVID-19

Get in-depth analysis of the COVID-19 impact on the Autoinjectors Market

Benchmarking the rapid strategy shifts of the Top 100 companies in the Autoinjectors Market

Request For Special Pricing
Report Code
MD 6494
Published ON
Dec, 2020
Choose License Type
BUY NOW
  • SHARE
X
Request Customization
Speak to Analyst
Speak to Analyst
OR FACE-TO-FACE MEETING
PERSONALIZE THIS RESEARCH
  • Triangulate with your Own Data
  • Get Data as per your Format and Definition
  • Gain a Deeper Dive on a Specific Application, Geography, Customer or Competitor
  • Any level of Personalization
REQUEST A FREE CUSTOMIZATION
LET US HELP YOU!
  • What are the Known and Unknown Adjacencies Impacting the Autoinjectors Market
  • What will your New Revenue Sources be?
  • Who will be your Top Customer; what will make them switch?
  • Defend your Market Share or Win Competitors
  • Get a Scorecard for Target Partners
CUSTOMIZED WORKSHOP REQUEST
ADJACENT MARKETS
REQUEST BUNDLE REPORTS
+1-888-600-6441
  • Call Us
  • +1-888-600-6441 (Corporate office hours)
  • +1-888-600-6441 (US/Can toll free)
  • +44-800-368-9399 (UK office hours)
CONNECT WITH US
ABOUT TRUST ONLINE
©2021 MarketsandMarkets Research Private Ltd. All rights reserved
...

Digital Virtual Assistant - MarketsandMarkets

Home